Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Rituximab, Venetoclax (ABT 199) and Bortezomib in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT04285268 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT04285268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04285268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Rituximab, Venetoclax (ABT 199) and Bortezomib in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 2
Overall status
Withdrawn
Start date
May 6, 2020
Completion date
September 30, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high grade b-cell lymphoma, not otherwise specified, recurrent burkitt lymphoma, recurrent diffuse large b-cell lymphoma, recurrent high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, refractory burkitt lymphoma, refractory diffuse large b-cell lymphoma, refractory high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements